Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


A novel mutation in the erythroid transcription factor KLF1 is likely responsible for ameliorating β-thalassemia major.

Fanis P, Kousiappa I, Phylactides M, Kyrri A, Hadjigavriel M, Christou S, Sitarou M, Kleanthous M.

Hum Mutat. 2019 Oct;40(10):1768-1780. doi: 10.1002/humu.23817. Epub 2019 Jun 24.


Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells.

Patsali P, Turchiano G, Papasavva P, Romito M, Loucari CC, Stephanou C, Christou S, Sitarou M, Mussolino C, Cornu TI, Antoniou MN, Lederer CW, Cathomen T, Kleanthous M.

Haematologica. 2019 Nov;104(11):e497-e501. doi: 10.3324/haematol.2018.215178. Epub 2019 Apr 19. No abstract available.


Short-hairpin RNA against aberrant HBBIVSI-110(G>A) mRNA restores β-globin levels in a novel cell model and acts as mono- and combination therapy for β-thalassemia in primary hematopoietic stem cells.

Patsali P, Papasavva P, Stephanou C, Christou S, Sitarou M, Antoniou MN, Lederer CW, Kleanthous M.

Haematologica. 2018 Sep;103(9):e419-e423. doi: 10.3324/haematol.2018.189357. Epub 2018 Apr 26. No abstract available.


Rapid and Sensitive Assessment of Globin Chains for Gene and Cell Therapy of Hemoglobinopathies.

Loucari CC, Patsali P, van Dijk TB, Stephanou C, Papasavva P, Zanti M, Kurita R, Nakamura Y, Christou S, Sitarou M, Philipsen S, Lederer CW, Kleanthous M.

Hum Gene Ther Methods. 2018 Feb;29(1):60-74. doi: 10.1089/hgtb.2017.190.


Hb A2 Episkopi - a novel δ-globin chain variant [HBD:c.428C>T] in a family of mixed Cypriot-Lebanese descent.

Lederer CW, Pavlou E, Tanteles GA, Evangelidou P, Sismani C, Kolnagou A, Sitarou M, Christou S, Hadjigavriel M, Kleanthous M.

Hematology. 2017 Jun;22(5):304-309. doi: 10.1080/10245332.2016.1265043. Epub 2016 Dec 22.


The molecular spectrum and distribution of haemoglobinopathies in Cyprus: a 20-year retrospective study.

Kountouris P, Kousiappa I, Papasavva T, Christopoulos G, Pavlou E, Petrou M, Feleki X, Karitzie E, Phylactides M, Fanis P, Lederer CW, Kyrri AR, Kalogerou E, Makariou C, Ioannou C, Kythreotis L, Hadjilambi G, Andreou N, Pangalou E, Savvidou I, Angastiniotis M, Hadjigavriel M, Sitarou M, Kolnagou A, Kleanthous M, Christou S.

Sci Rep. 2016 May 20;6:26371. doi: 10.1038/srep26371.


Hb Famagusta--analysis of a novel δ-globin chain variant [HBD:c.60C>A] in four families with diverse globin genotypes.

Lederer CW, Pavlou E, Makariou C, Hadjilambi G, Andreou N, Hadjigavriel M, Kolnagou A, Sitarou M, Christou S, Kleanthous M.

Ann Hematol. 2014 Sep;93(9):1625-7. doi: 10.1007/s00277-013-1996-6. Epub 2014 Jan 23. No abstract available.


Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.

Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M.

Haematologica. 2009 Dec;94(12):1777-8. doi: 10.3324/haematol.2009.009118. Epub 2009 Oct 8. No abstract available.


Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004.

Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M.

Haematologica. 2006 Sep;91(9):1187-92.


Update on fertility in thalassaemia major.

Skordis N, Petrikkos L, Toumba M, Hadjigavriel M, Sitarou M, Kolnakou A, Skordos G, Pangalou E, Christou S.

Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:296-302. Review.


Supplemental Content

Loading ...
Support Center